Related Experiment Video
Updated: Oct 18, 2026
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
[Anti-angiogenesis: a new approach to tumor therapy?]
D Schiefer1, C Gottstein, V Diehl
1Klinik I für Innere Medizin, Universität zu Köln.
Background:
The overall mortality due to metastatic cancer has not or only minimally been reduced in spite of intensive research and many innovations in the field of conventional antineoplastic therapy in the past decade. In the last years it has become a fact that tumor growth is angiogenesis-dependent. Therefore, inhibitors of angiogenesis are a new class of antineoplastic substances with a novel mechanism of action that might be a powerful complement to conventional cytostatic therapy. SUBSTANCES AND CLINICAL TRIALS: Inhibitors of tumor-angiogenesis which have entered clinical trials, with their results published until December 1998 are discussed here. Most results originate from phase-I or phase-II clinical trials. They are discussed and compared in respect to toxicity and response. Also some substances with high therapeutic potential which are still in preclinical testing are discussed.
Results:
Many of the investigated angiogenesis inhibitors demonstrated anti-tumor effects in phase-I or phase-II clinical trials. The commonest manifestation was stable disease, followed by partial remissions. In a few cases, complete remissions were observed. The toxicities of these substances differ both in type and degree of side effects.
Conclusion:
Some antiangiogenic drugs appear to be promising candidates for a clinical use in the therapy of solid tumors. Further conclusions can only be drawn after evaluation of the results of ongoing phase-III clinical trials.
Insights
Angiogenesis inhibitors show promise in treating solid tumors by targeting tumor growth. Early clinical trials indicate anti-tumor effects, but further research is needed.
Area of Science:
- Oncology
- Pharmacology
Context:
- Metastatic cancer mortality remains high despite conventional therapies.
- Tumor growth is critically dependent on angiogenesis.
- Angiogenesis inhibitors represent a novel therapeutic strategy.
Purpose:
- To review angiogenesis inhibitors that entered clinical trials by December 1998.
- To compare their toxicity and efficacy based on Phase I/II data.
- To discuss promising agents in preclinical development.
Summary:
- Several angiogenesis inhibitors demonstrated anti-tumor activity in early clinical trials.
- Observed responses included stable disease, partial remissions, and rare complete remissions.
- Toxicity profiles varied significantly among the agents studied.
Impact:
- Angiogenesis inhibitors show potential as a complementary therapy for solid tumors.
- Further evaluation in Phase III trials is crucial to confirm clinical utility.
- This review provides insights into early-stage anti-angiogenic drug development.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:10Mechanism of Angiogenesis
01:24Regulation of Angiogenesis and Blood Supply
02:17The Tumor Microenvironment